| Identification | Back Directory | [Name]
Trastuzumab | [CAS]
180288-69-1 | [Synonyms]
Herceptin
RhuMab HER2
Trastuzumab Beta
TRASTUZUMAB 95 % +
TRASTUZUMAB 98 % +
Trastuzumab USP/EP/BP
TrastuzuMab(Herceptin)
Trastuzumab (anti-HER2)
Trastuzumab,Stock solution
Trastuzumab - 20mg/ml in PBS
Anti HER2, Ig gamma-1 chain C region
Recombinant humanized anti-HER2 antibody
IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer | [Molecular Formula]
C10H14N6O5 | [MDL Number]
MFCD03702625 | [MOL File]
180288-69-1.mol | [Molecular Weight]
298.255 |
| Hazard Information | Back Directory | [Indications]
The introduction of herceptin (Trastuzumab) into clinical
practice for the treatment of breast cancer marks a
major advance in the use of monoclonal antibody cancer
therapy. Herceptin is a humanized antibody directed
against the HER-2 antigen that is overexpressed
on the tumor cell surface in approximately 25% of
breast cancer patients. HER-2/neu/erbB2 overexpression
marks an aggressive estrogen receptor–negative
form of breast cancer. Therefore, a therapeutic agent
selective for this target is particularly valuable.
Herceptin is administered by intravenous infusion and
in conjunction with paclitaxel can extend survival in
patients with HER-2/neu/erbB2 overexpressing metastatic
breast cancer.Herceptin use is associated with infusion-
related hypotension, flushing and bronchoconstriction,
and skin rash but no bone marrow toxicity.
Herceptin appears to sensitize patients to cardiotoxicity,
an important concern in patients also receiving
doxorubicin. |
|
|